Last Updated : April 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Tukysa | tucatinib | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Twynsta | Telmisartan / Amlodipine | Hypertension | Cancelled | |||
| Twynsta | Telmisartan/ Amlodipine | Hypertension | List | Complete | ||
| Tykerb (in combination with Letrozole) | Lapatinib | Metastatic Breast Cancer | Do not reimburse | Complete | ||
| Tysabri | natalizumab | Multiple Sclerosis, relapsing-remitting | Withdrawn | |||
| Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | Do not list | Complete | ||
| Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
| Uloric | Febuxostat | Gout | List with clinical criteria and/or conditions | Complete | ||
| Ultibro Breezhaler | Indacaterol/glycopyrronium | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
| Ultomiris | ravulizumab | Atypical hemolytic uremic syndrome | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 20, 2024